MorphoSys AG with ticker code (MOR) now have 1 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 43.23 and 43.23 with the average target price sitting at 43.23. Given that the stocks previous close was at 28.89 this would indicate that there is a potential upside of 49.6%. The 50 day MA is 31.04 while the 200 day moving average is 30.5. The company has a market cap of $3,901m. You can visit the company’s website by visiting: http://www.morphosys.com

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer’s diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys’ investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.

Join us on our new LinkedIn page

Follow us on LinkedIn

You can read the full MOR archive by clicking the EPIC code.